Wells Fargo Maintains Overweight on Cabaletta Bio, Lowers Price Target to $20
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Derek Archila maintains an Overweight rating on Cabaletta Bio (NASDAQ:CABA) but lowers the price target from $35 to $20.
August 12, 2024 | 5:41 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Wells Fargo analyst Derek Archila maintains an Overweight rating on Cabaletta Bio but lowers the price target from $35 to $20.
The lowered price target from $35 to $20 suggests a less optimistic outlook for Cabaletta Bio's stock performance, which could lead to a short-term negative impact on the stock price despite the maintained Overweight rating.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100